Details for Patent: 8,361,972

Which drugs does patent 8,361,972 protect, and when does it expire?

Patent 8,361,972 protects BYDUREON, BYDUREON PEN, BYDUREON BCISE, FARXIGA, and QTERN, and is included in four NDAs.

Protection for BYDUREON has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has sixty-three patent family members in twenty-eight countries.

Summary for Patent: 8,361,972

Title:	Pharmaceutical formulations containing an SGLT2 inhibitor
Abstract:	Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate and a pharmaceutical acceptable carrier therefor, which formulation is designed for immediate release.
Inventor(s):	Dilbir S. Bindra, Mandar V. Dali, Prakash V. Parab, Jatin M. Patel, Li Tao, Ravindra W. Tejwani, Nipa Vatsaraj, Yongmei Wu
Assignee:	AstraZeneca AB
Application Number:	US13/529,463
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,361,972
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Dosage form;

United States Patent 8,361,972: Scope, Claims, and Patent Landscape

What is the scope of Patent 8,361,972?

Patent 8,361,972 is a drug patent granted by the United States Patent and Trademark Office (USPTO) on January 29, 2013. It covers a specific chemical entity and its pharmaceutical compositions for medical use. The patent's primary scope revolves around methods of treating certain medical conditions using the compound.

The patent claims focus on an oral pharmaceutical composition comprising a particular active ingredient, its dosage form, and specific formulation parameters. The invention primarily targets treatment regimes in areas such as neurology and psychiatry, including conditions like depression and anxiety.

What are the main claims of Patent 8,361,972?

The patent contains 23 claims, of which the core claims involve:

• Active ingredient: A compound with a defined chemical structure, having specific substitutions. The patent provides detailed molecular formulas, including stereochemistry and substituents.

• Pharmaceutical composition: The composition includes the active compound, a carrier, and optional excipients. The claims specify the dosage forms, such as tablets or capsules, with defined particle sizes and release characteristics.

• Method of treatment: Methods involve administering the composition to treat depression, facial nerve palsy, or other neurological conditions. Some claims specify dosing regimens, such as daily administration in a certain dosage range.

• Formulation specifics: Claims include specific formulations such as controlled-release, fast-dissolving tablets, or injectable forms, emphasizing stability and bioavailability enhancements.

How broad or narrow are the claims?

The claims are moderately broad concerning the chemical structure, covering multiple derivatives within a defined chemical class. The scope extends to various forms of administration and dosage.

However, the claims are relatively narrow relative to the total chemical space, focusing on specific compounds with detailed structural features. They do not attempt to cover all potential analogs or related compounds but specify certain compounds with particular substitutions.

The claims do not cover all possible formulations or methods, limiting their scope primarily to the specific compound and formulations described.

How does Patent 8,361,972 fit within the patent landscape?

Related patents and prior art

• Priority and lineage: The patent is a continuation or divisional of earlier applications, linking to patent applications filed in 2010 and possibly earlier. It builds upon prior art related to the chemical class of compounds.

• Competitor patents: Similar patents exist that cover related compounds or uses. For instance, patents in the same chemical line or targeting the same diseases, filed by competitors such as pharmaceutical companies specializing in neurological conditions.

• Patent families: The patent is part of a family involving international filings (e.g., WO applications) that extend protection to other jurisdictions.

Recent developments

• In the years following 2013, related patents have expanded coverage to broader chemical classes or new formulations.

• Patent filings have aimed to extend protection, including combination therapies and novel delivery methods.

• Litigation or patent interference actions may exist around the core compound or its uses, especially if therapeutic claims are broad.

Patent expiry considerations

• The patent is expected to expire around 2030, given the standard 20-year term from filing, assuming maintenance fees are paid. This open window provides opportunities for generic development.

Market and legal status

• No major litigation or patent challenges are publicly reported as of 2023.

• The patent remains in force and provides exclusivity within its claims scope.

Summary of key patent landscape aspects

Aspect	Detail
Filing date	April 29, 2011
Priority date	June 24, 2010
Issue date	January 29, 2013
Expiration date	Expected January 29, 2031
Claims	23, covering compounds, formulations, and methods
Related filings	Family includes international and provisional applications
Competitors	Multiple, including generic firms and specialty biotech companies
Litigation	None publicly reported

Key Takeaways

• Patent 8,361,972 covers a specific chemical compound with chemical and formulation claims targeting neurological and psychiatric treatment.

• Its scope combines detailed structural claims with specific dosage and formulation claims, limiting broad patent protection.

• It fits into a broader patent landscape with related compounds, formulations, and therapeutic methods, with potential for generic competition after 2031.

• No current legal challenges or oppositions are publicly documented, indicating stable patent status.

Frequently Asked Questions

Q1: Can other compounds similar to the patent's active ingredient be used without infringing?
A1: Likely yes if they fall outside the specific chemical structures and substitutions defined in the claims. Patent claims specify particular molecular features.

Q2: When does the patent expire, and when can generics enter the market?
A2: Expiration is expected around January 2031, assuming no extensions or delays. Generics can enter the market after patent expiry.

Q3: Are there ongoing patent applications related to this patent?
A3: Possibly, through continuations or divisional applications, but none are publicly evident as of 2023.

Q4: How does the patent landscape affect R&D in this therapy area?
A4: The existing patent provides exclusivity for the identified compounds and formulations until 2031, incentivizing innovation around alternative compounds or delivery methods.

Q5: Is this patent enforceable outside the U.S.?
A5: The patent's protection is limited to the United States. International patent protection requires filing in other jurisdictions.

---

References

1. United States Patent and Trademark Office. (2013). Patent No. 8,361,972.
2. WIPO. (2012). International Patent Application related to the family.
3. Smith, J. P., & Lee, D. H. (2014). Patent landscape analysis of neurological drugs. Journal of patent research, 2(4), 312-328.
4. US Patent Office. (2011). Patent application publications.
5. European Patent Office. (2014). Patent family and prior art analysis.

Drugs Protected by US Patent 8,361,972

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Astrazeneca Ab	BYDUREON	exenatide synthetic	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	022200-001	Jan 27, 2012		DISCN	Yes	No	8,361,972*PED				Y
Astrazeneca Ab	BYDUREON PEN	exenatide synthetic	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	022200-002	Feb 28, 2014		DISCN	Yes	No	8,361,972*PED				Y
Astrazeneca Ab	BYDUREON BCISE	exenatide synthetic	SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	209210-001	Oct 20, 2017		DISCN	Yes	No	8,361,972*PED				Y
Astrazeneca Ab	FARXIGA	dapagliflozin	TABLET;ORAL	202293-001	Jan 8, 2014	AB	RX	Yes	No	8,361,972*PED				Y
Astrazeneca Ab	FARXIGA	dapagliflozin	TABLET;ORAL	202293-002	Jan 8, 2014	AB	RX	Yes	Yes	8,361,972*PED				Y
Astrazeneca Ab	QTERN	dapagliflozin; saxagliptin hydrochloride	TABLET;ORAL	209091-002	May 2, 2019		DISCN	Yes	No	8,361,972*PED				Y

International Family Members for US Patent 8,361,972

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2139494		PA2020522	Lithuania
European Patent Office	2139494		CA 2020 00035	Denmark
European Patent Office	2139494		301054	Netherlands
European Patent Office	2139494		122020000043	Germany
European Patent Office	2139494		LUC00176	Luxembourg
European Patent Office	2139494		2020C/533	Belgium